Fig. 1: Response outcomes of the CBF-AML patients after induction therapy. | Blood Cancer Journal

Fig. 1: Response outcomes of the CBF-AML patients after induction therapy.

From: Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients

Fig. 1

A response outcomes of all patients with CBFB::MYH11. B, C response outcomes of CBFB::MYH11 cohort with or without FLT3-ITD/NRAS/KIT mutation. D response outcomes of all patients with RUNX1::RUNX1T1. E, F response outcomes of RUNX1::RUNX1T1 cohort with or without FLT3-ITD/NRAS/KIT mutation.

Back to article page